AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Diamyd Medical: Fund invests SFR 35 M in Diamyd.
Diamyd Medical has accepted an offer from an investment fund managed from New York by a Swedish-American team to issue 291,667 new B shares in a direct placement at SFR 120/share. The issue price corresponds to the average market price of the past 30 trading days. Total proceeds for Diamyd amounts to SFR 35 M. The company's current funds are dedicated to finance the ongoing Phase III programme of the diabetes vaccine Diamyd, where results are expected during spring 2011. Diamyd is regularly evaluating new external and internal …
-
- Diamyd Medical: Diamyd Phase III study approved by six European countries.
-
News wire article from: Chemical Business Newsbase
November 6, 2008
700+ words
-
- Diamyd Medical's European Phase III trial does not meet primary endpoint.
-
News wire article from: Europe Intelligence Wire
May 9, 2011
700+ words
-
- Diamyd Medical announces Phase III clinical trials plan for Diamyd in Type 1...
-
News wire article from: Chemical Business Newsbase
March 8, 2007
700+ words
-
- NEJM publishes Diamyd Medical's Phase III trial data.
-
News wire article from: Europe Intelligence Wire
February 2, 2012
700+ words
-
- Diamyd Medical: Diamyd's Phase III studies continue to follow plan.
-
News wire article from: Chemical Business Newsbase
April 28, 2010
700+ words
